Erythema following imatinib mesylate.
Duncan
Edward
E
Department of Haematology, Kings College Hospital, Denmark Hill, London, UK. er_duncan@hotmail.com
Raj
Kavita
K
Mufti
Ghulam
G
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D004791:Enzyme Inhibitors / Q000009:adverse effects; D004890:Erythema / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases